Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount [Reuters]
Coherus BioSciences, Inc. (CHRS)
Last coherus biosciences, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.coherus.com
Company Research
Source: Reuters
Coherus prices biosimilar to Amgen's Neulasta at 33 percent discount | Reuters 1 Min Read (Reuters) - Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc’s infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV’s biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call. Udenyca, the second approved copycat version to Neulasta, received approval from the U.S. Food and Drug Administration last week. Neulasta, used to fight infections in cancer patients, has a list price of $6,231 per unit, and brought Amgen revenue of $4.53 billion in 2017. Coherus on Thursday also reported a bigger-than expected quarterly loss of 87 cents per share. Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Maju Samuel All quotes delayed a minimum of 15 minutes. See here for a complete list of exch
Show less
Read more
Impact Snapshot
Event Time:
CHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CHRS alerts
High impacting Coherus BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
CHRS
News
- Coherus Biosciences: Dumping One Drug But Showing Promise With Another [Seeking Alpha]Seeking Alpha
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its price target lowered by analysts at HC Wainwright from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.MarketBeat
- Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Global Neutropenia Market Competitive Analysis and Forecast Report to 2028, Featuring BeyondSpring Pharmaceuticals, Coherus Biosciences, Myelo Therapeutics and Spectrum Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
CHRS
Earnings
- 3/13/24 - Miss
CHRS
Sec Filings
- 3/28/24 - Form S-8
- 3/15/24 - Form 10-K
- 3/13/24 - Form 8-K
- CHRS's page on the SEC website